Inhibition of the mevalonate pathway augments the activity of pitavastatin against ovarian cancer cells
Open Access
- 14 August 2017
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , 1-13
Abstract
Only 40% of patients with advanced ovarian cancer survive more than 5 years. We have previously shown that pitavastatin induces regression of ovarian cancer xenografts in mice. To evaluate whether the response of ovarian cancer cells to pitavastatin is potentiated by farnesyl diphosphate synthase inhibitors or geranylgeraniol transferase I inhibitors, we evaluated combinations of pitavastatin with zoledronic acid, risedronate and GGTI-2133 in a panel of ovarian cancer cells. Pitavastatin (IC50 = 0.6–14 μM), zoledronic acid (IC50 = 21–57 μM), risedronate (IC50 > 100 μM) or GGTI-2133 (IC50 > 25 μM) inhibited the growth of ovarian cancer cell cultures. Combinations of pitavastatin with zoledronic acid displayed additive or synergistic effects in cell growth assays in 10 of 11 cell lines evaluated as well as in trypan blue exclusion, cellular ATP or caspase 3/7, 8 and 9 assays. Pitavastatin reduced levels of GGT-IIβ and the membrane localization of several small GTPases and this was potentiated by zoledronic acid. siRNA to GGT-Iβ and GGT-IIβ used in combination, but not when used individually, significantly increased the sensitivity of cells to pitavastatin. These data suggest that zoledronic acid, a drug already in clinical use, may be usefully combined with pitavastatin in the treatment of ovarian cancer.Keywords
This publication has 65 references indexed in Scilit:
- Rethinking ovarian cancer: recommendations for improving outcomesNature Reviews Cancer, 2011
- Bisphosphonates significantly increase the activity of doxorubicin or vincristine against canine malignant histiocytosis cellsVeterinary and Comparative Oncology, 2011
- Recent progress in the diagnosis and treatment of ovarian cancerCA: A Cancer Journal for Clinicians, 2011
- Tumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancerBMC Cancer, 2010
- Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevanceBMC Cancer, 2010
- Inhibitors of Protein Geranylgeranyltransferase I and Rab Geranylgeranyltransferase Identified from a Library of Allenoate-derived CompoundsJournal of Biological Chemistry, 2008
- Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcomaBritish Journal of Cancer, 2007
- Chemical genetics identifies Rab geranylgeranyl transferase as an apoptotic target of farnesyl transferase inhibitorsCancer Cell, 2005
- Therapy Insight: potential of statins for cancer chemoprevention and therapyNature Clinical Practice Oncology, 2005
- Regulation of the mevalonate pathwayNature, 1990